© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Bone Biologics Corporation (BBLG) stock surged +6.95%, trading at $2.00 on NASDAQ, up from the previous close of $1.87. The stock opened at $1.90, fluctuating between $1.84 and $2.39 in the recent session.
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
| Employees | 2 |
| Beta | 0.52 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |